11 Best Wide Moat Stocks to Buy Right Now

10. Amgen Inc. (NASDAQ:AMGN)

Number of Hedge Fund Holders: 62

Amgen Inc. (NASDAQ:AMGN) is one of the Best Wide Moat Stocks to Buy Right Now. The company possesses a wide economic moat, which is backed by its intellectual property and brand reputation. On October 6, the company announced the launch of AmgenNow, which is a new direct-to-patient program starting with Repatha® (evolocumab). This comes after the landmark results reflecting that Repatha significantly reduced the risk of major adverse cardiovascular events in individuals without a prior history of heart attack or stroke in the VESALIUS-CV Phase 3 trial. Amgen Inc. (NASDAQ:AMGN) further added that, in support of the Trump Administration’s focus on lowering the drug prices for Americans, Repatha would be available via AmgenNow at a monthly price of $239, ~60% lower than the current US list price.

Elsewhere, Amgen Inc. (NASDAQ:AMGN) announced a $650 million expansion of the US manufacturing network, targeting to support increased drug production at its biologics manufacturing facility in Juncos and integrate innovative advanced technologies across the operations process. Notably, the expansion strengthens Amgen Inc. (NASDAQ:AMGN)’s commitment to the US biomanufacturing and the resilience of its global supply chain.

Aristotle Capital Management, LLC, an investment management company, released its Q2 2025 investor letter. Here is what the fund said:

“Amgen Inc. (NASDAQ:AMGN), the biopharmaceutical company, was one of the largest detractors for the quarter. While the company’s branded drugs continued to advance (a previously identified catalyst), with cholesterol medicine Repatha, osteoporosis treatment Evenity and bone-strengthening drug Prolia all growing sales in the double digits, concerns surrounding potential tariff impacts, tax reform and pressure on drug prices weighed on shares. We believe it is too early to assess the full impact of these macro uncertainties and are confident in Amgen’s demonstrated ability to adapt through evolving policy and pricing dynamics. The company reaffirmed its long-term commitment to domestic manufacturing and innovation through its upcoming $2 billion expansions in Ohio and North Carolina, building on more than $5 billion in U.S. operational investments since 2017. Furthermore, Amgen continued to advance its robust pipeline, as its 1L bemarituzumab (bema) phase 3 trial for gastric cancer met its primary endpoint, and MariTide, the company’s weight-loss drug, demonstrated strong efficacy in phase 1 and 2 trials. MariTide, which could offer more convenient monthly dosing compared to daily or weekly regimens, showed promising early results, though tolerability will be an important focus heading into phase 3. Management noted that modified dose ramp-up strategies may help mitigate these effects. Despite near-term pressures, we remain encouraged by Amgen’s continued market share gains across key therapies and the potential to enhance the company’s competitiveness and resilience in a dynamic healthcare landscape.”